Total Funding
3
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
PrognosDx Health develops and commercializes epigenetic tests based on histone modification patterns.
Joseph J. Vallner: Chief Executive Officer & Board Member
About the Company
PrognosDx Health, Inc., a biotechnology company, develops and commercializes epigenetic tests based on histone modification patterns. The company also provides services, such as pharmaceutical research-clinical sample analysis, clinical patient sample analysis tests for other cancers, and prostate cancer patient prognosis test. Its products are
used in the development of cancer prognostic assays, therapeutic response prediction assays, and research tools and reagents. The company’s tissue-based global cellular histone biomarkers are prognostic for various cancers, such as prostate, pancreatic, breast, bladder, kidney, gastrics, colon, and lung cancer. PrognosDx Health, Inc. was incorporated in 2008 and is based in Palo Alto, California.
